Sevoflurane Inhalation
Sevoflurane
100%
BAXTER HEALTHCARE CORPORATION (Deerfield)
| Pack size | 250ml Metallic Bottle |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | MEDWING MEDICAL LLC |
| Retail Price | 555.63 AED |
Indications
Sevoflurane Inhalation is used for:
General anaesthesia
Adult Dose
Inhalation
Induction and maintenance of general anaesthesia
Adult: Induction: Premedicated patient: Up to 5% v/v w/ oxygen (or mixture of oxygen and nitrous oxide), individualised according to age and clinical status.
Unpremedicated patient: Up to 8% v/v. Maintenance: 0.5-3% v/v w/ or w/o nitrous oxide. Doses are given via calibrated vaporiser.
Child Dose
Inhalation
Induction and maintenance of general anaesthesia
Child: Induction: Up to 7% v/v w/ oxygen (or mixture of oxygen and nitrous oxide) given via calibrated vaporiser.
Renal Dose
Administration
Contra Indications
Known or suspected susceptibility to malignant hyperthermia. Previous hypersensitivity.
Precautions
Patient w/ increased intracranial pressure, neuromuscular disease (esp Duchenne muscular dystrophy), mitochondrial disorders. Patient who are hypovolaemic, hypotensive, haemodynamically compromised, at risk of QT prolongation. Hepatic and renal impairment. Childn. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor for BP, temp, heart rate and rhythm, oxygen saturation, end-tidal CO2, and end-tidal drug concentrations prior to and throughout anaesthesia. Monitor the temp of CO2 absorbent canister. Recovery from general anaesthesia should be assessed carefully before discharge.
Lactation: excreted in breast milk; no adverse effect on nursing infant
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women; in animal reproduction studies, reduced fetal weights were noted following exposure to 1 MAC sevoflurane for three hours a day during organogenesis
There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans Sevoflurane has been used as part of general anesthesia for elective cesarean section in women; there were no untoward effects in mother or neonate; the safety of sevoflurane in labor and delivery has not been demonstrated
Lactation
The concentrations of sevoflurane in milk are probably of no clinical importance 24 hours after anesthesia; because of rapid washout, sevoflurane concentrations in milk are predicted to be below those found with many other volatile anesthetics
Interactions
May enhance effect and duration of competitive neuromuscular blockers. Metabolism and toxicity increased by cytochrome P450 isoenzyme CYP2E1 inducers including isoniazid and alcohol. Increased risk of cardiac arrhythmias when used with epinephrine or norepinephrine.
Adverse Effects
Side effects of Sevoflurane :
Cardiorespiratory depression, hypotension, bradycardia; laryngospasm, increased cough and salivation; urinary retention, acute renal failure, changes in liver enzyme values, liver damage; nausea, vomiting, delirium, seizure; rash, urticaria, pruritus, dyspnoea, wheezing, chest discomfort, bronchospasm, anaphylactic/anaphylactoid reaction; agitation, dystonic movements (childn).
Potentially Fatal: Malignant hyperthermia. Rarely, hyperkalaemia resulting in cardiac arrhythmias, particularly in childn w/ neuromuscular disease.
Mechanism of Action
Sevoflurane is a volatile halogenated general anaesthetic which causes a reversible loss of consciousness and pain sensation, suppression of voluntary motor activity, modification of autonomic reflexes, depression of the respiratory and CV systems. It also has muscle relaxant properties.
Note
Sevoflurane 100% Inhalation manufactured by BAXTER HEALTHCARE CORPORATION (Deerfield). Its generic name is Sevoflurane. Sevoflurane is availble in United Arab Emirates.
Farmaco UAE drug index information on Sevoflurane Inhalation is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.